SWISS drug ingredients maker Lonza Group is maintaining its full-year outlook amid positive momentum in its core healthcare businesses and headwinds in its specialty ingredients segment, the company said in a business update provided on Thursday.
Group chief executive Marc Funk said:"Q1 results demonstrate that Lonza today has two segments operating in different markets, and growing at varying paces; so their performance and challenges should not be compared... The most recent segment alignment will support us as we continue to capitalise on increased investment focus, synergies and productivity within the segments. The alignment is a priority to ensure we remain firmly on our growth trajectory.
Nonetheless, the group is maintaining its outlook for the year. It expects mid-to-high single digit sales growth, and a sustained core earnings before interest, tax, depreciation and amortisation margin level for 2019.